Authors
Liana Fraenkel, Joan M Bathon, Bryant R England, E William St. Clair, Thurayya Arayssi, Kristine Carandang, Kevin D Deane, Mark Genovese, Kent Kwas Huston, Gail Kerr, Joel Kremer, Mary C Nakamura, Linda A Russell, Jasvinder A Singh, Benjamin J Smith, Jeffrey A Sparks, Shilpa Venkatachalam, Michael E Weinblatt, Mounir Al‐Gibbawi, Joshua F Baker, Kamil E Barbour, Jennifer L Barton, Laura Cappelli, Fatimah Chamseddine, Michael George, Sindhu R Johnson, Lara Kahale, Basil S Karam, Assem M Khamis, Iris Navarro-Millán, Reza Mirza, Pascale Schwab, Namrata Singh, Marat Turgunbaev, Amy S Turner, Sally Yaacoub, Elie A Akl
Publication date
2021/7
Journal
Arthritis & Rheumatology
Volume
73
Issue
7
Pages
1108-1123
Description
Objective
To develop updated guidelines for the pharmacologic management of rheumatoid arthritis.
Methods
We developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.
Results
The guideline addresses treatment with disease‐modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high‐risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous …
Scholar articles
L Fraenkel, JM Bathon, BR England, EW St. Clair… - Arthritis & Rheumatology, 2021